Looking at PE 22-28 as a fast‑acting antidepressant peptide – thoughts?

Posted by sleep_coastal in Research & News - 5 points, 4 comments.

I came across the PE 22-28 entry on the site and it got me thinking about how fast‑acting antidepressants are talked about these days. The description says it’s a spadin‑derived peptide that blocks the TREK‑1 potassium channel, which in animal models boosts serotonergic signaling and neurogenesis faster than typical SSRIs. Anecdotally, I’ve noticed that when I experiment with compounds that affect glutamate or GABA pathways, mood shifts can feel pretty immediate, but the safety picture is always vague for peptides that haven’t left the lab.

Since human data is basically nonexistent, I’m cautious about jumping in without solid bloodwork or a clinician’s input. Still, the mechanism lines up with what some researchers are chasing for rapid‑acting mood aids, and it’d be interesting to see if any small human trials pop up. Has anyone here tracked mood or cognitive changes with something that targets TREK‑1, even indirectly? What markers would you look at first if you tried it?

Comments

• greg_codes: Haven't tried PE 22-28 itself but i've tracked mood stuff with other compounds and honestly the hard part is quantifying mood objectively? Like HRV and sleep are easy to pull from your watch but mood is just a daily 1-10 self-rating which could be placebo heaps of the time. Ngl i'd want morning cortisol, maybe a PHQ-9 done weekly, and resting HR trends as a proxy for nervous system state. TREK-1 is interesting because it's the same rapid-onset angle ketamine researchers chase but through a tota
• sleep_coastal: Yeah the measurement problem is real. I've been doing daily 1-10 mood logging for a while and you're right, it's mushy. HRV and resting HR I already pull from my watch so that part's easy. The PHQ-9 weekly idea is actually smart, gonna steal that. Morning cortisol I could add through a lab panel but that gets pricey fast. The ketamine parallel you drew is exactly what got my attention too, same rapid-onset goal but totally different pharmacology. Still, potassium channel blocking gives me more
• fasted_scientist: Spot on about the mood tracking problem, a daily 1-10 is basically useless for picking up subtle shifts. PHQ-9 weekly is a decent shout, at least it's a validated scale rather than vibes. But even cortisol and HRV are proxies, they tell you something changed but not what or why. The potassium channel thing is what puts me off PE 22-28 tbh. TREK-1 isn't just in the brain, it's expressed in cardiac tissue too. Blocking it systemically feels like a gamble when the delivery route matters so much. K
• sleep_coastal: The cardiac point is a really good catch, I hadn't thought about TREK-1 expression outside the brain. That kinda changes the risk calculus for me. Intranasal might limit systemic exposure but even that's a guess without real pharmacokinetic data. I'll look into the PHQ-9 angle for tracking, that's smarter than what I was doing. Did you end up passing on PE 22-28 entirely because of the cardiac concern, or were you weighing other compounds in the same space?

Community discussion - research and educational context only. Not medical advice.